We are driven by our aim to improve access and affordability of medicines. The generics business delivers a pipeline of products that address unmet patient needs. Sustainability is at the core of our business model, which is built on the pillars of market leadership, productivity and innovation.
Our strong presence in the generics market has been built on the back of new product launches, investments in existing brands, a diversified portfolio that spans therapeutic categories and dosage forms, and strategic digital partnerships for investor and customer connect.
NORTH AMERICA
We have been present in the North American region, comprising USA and Canada, since the mid-1990s. It is our biggest business, with revenue in FY’22 touching a historical milestone of $1 billion, and the revenue for FY’24 closing on approximately $1.6 billion. Our portfolio covers over 230 products across the retail, institutional and over-the-counter (OTC) segments.
Our pipeline includes several first-to-market drugs, complex products across drug-device combinations, peptides, and long-acting injectables.
Highlights
In September 2022, we launched Lenalidomide Capsules, a therapeutic equivalent generic version of REVLIMID® (lenalidomide) Capsules approved by U. S. Food and Drug Administration (USFDA). With this volume-limited launch, we became eligible for first-to-market, 180 days of generic drug exclusivity for Dr. Reddy’s Lenalidomide Capsules in 2.5 mg and 20 mg strengths.
Our growth in North America in FY’24 was largely on account of increased volumes in the base business, including Lenalidomide as well as revenues from new products launched in FY2024. With patients at our core, in 2023 December we entered into an exclusive collaboration with Coya Therapeutics, Inc. for Development and Commercialization of COYA 302, an Investigational Combination Therapy for Treatment of Amyotrophic Lateral Sclerosis (ALS). Read more about this here. We acquired a leading women’s health and dietary supplements portfolio, MenoLabs®. We collaborated with Mark Cuban Cost Plus Drug Company, aimed at increasing access to essential medications for Wilson disease patients. We launched 20 new products, including Treprostinil Injection, Regadenoson Injection in the U.S. as well as products acquired from Mayne Pharma and filed 17 new Abbreviated New Drug Applications (ANDAs) with the US Food and Drug Administration (USFDA).
For selected drugs in our portfolio, we offer patient support services. We also partner with specialty pharmacies to unlock the potential of our complex and injectable generics in the growing specialty drug segment. One of the most recent ones being patient support services for Dr. Reddy’s Sapropterin Dihydrochloride. The services included a patient hub, co-pay assistance, benefits/reimbursement liaison, and nutrition and nursing support.
In addition, we have also launched our own digital marketplace for the institutional segment, DrReddysDirect.com.
In the pipeline
In keeping with the market, we are creating different routes and enhancing our digital marketing and analytics capabilities, and expanding direct sales through partnerships with digital platforms. We are also deepening presence in the OTC and e-commerce segments.
For the OTC business, we have invested in creating a high-growth direct business channel – e-commerce, and are working with multiple e-commerce players, the primary one being Amazon. Through partnerships, we will add more prducts to this channel.
EUROPE
We currently serve patients in over 14 European countries, with our portfolio of generic and biosimilar medicines and OTC products across therapeutic categories.
As healthcare challenges rise globally, we remain committed to increasing access to affordable medicines and developing products to serve unmet needs. Our generic medications are identical to approved brand-name drugs but often at a fraction of the costs – providing essential savings to the countries’ healthcare systems and patients.
While we continue accelerating access in Europe, we expanded our reach for consumer healthcare products by launching the anti-hay fever medicine Histallay® as an OTC, making it available for patients faster. Our bevacizumab biosimilar received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK. Another essential addition to our portfolio is the drug-free migraine management wearable, Nerivio®, currently available in Germany, Spain and the UK.
In addition to the Dr. Reddy’s Laboratories, we work through our German subsidiaries betapharm and Nimbus Health GmbH (Nimbus Health). While betapharm is a trusted brand for generics and OTC medicines, Nimbus Health is a licensed pharmaceutical wholesaler focusing on medical cannabis. Medical cannabis is increasingly used to address and treat unmet medical needs, especially in pain management and CNS. As more European countries adopt the usage of medical cannabis, Nimbus Health will access additional geographies.
As part of the growth strategy for Europe, we will continue to explore organic and inorganic opportunities. The latest example is the signed definitive agreement with Haleon plc, a leading consumer healthcare company, for the purchase of shares of Northstar Switzerland SARL, a Haleon group company, to acquire Haleon’s global portfolio of consumer healthcare brands in the Nicotine Replacement Therapy (“NRT”) category outside of the United States. The portfolio to be acquired consists of Nicotinell, a global leader in the NRT category with an extensive footprint in over 30 countries spanning Europe, Asia including Japan, and Latin America, and local market-leading brand names of the product – Nicabate in Australia, Thrive in Canada, and Habitrol in New Zealand and Canada. The proposed acquisition will include all formats, such as lozenge, patch, gum, and pipeline products, in all applicable global markets outside of the United States.
For more information, please visit our country sites:
USA
Canada
Austria
Czech Republic
Denmark
Finland
France
Germany (betapharm)
Netherlands
Portugal
Romania
Slovakia
Sweden
Italy
Spain
United Kingdom
